Cytogenetic Subclone Burden: A New Biomarker Predicting Chronic Lymphocytic Leukemia Patients Outcome

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, primarily affecting older individuals.
• CLL exhibits a variable disease course, necessitating improved risk stratification methods.
• Cytogenetic abnormalities, such as 17p and 11q deletions, are crucial prognostic factors in CLL.

Purpose of the Study:

• To evaluate the prognostic impact of quantifying 17p deletion (17p del) and 11q deletion (11q del) cytogenetic subclones in CLL patients.
• To determine if subclone burden influences key clinical outcomes.
• To assess the utility of 17p del and 11q del quantification for refining CLL risk stratification.

Main Methods:

• A prospective study involving 100 patients diagnosed with CLL.
• Fluorescence In Situ Hybridization (FISH) technique was employed to assess the burden of 17p del and 11q del cytogenetic subclones.
• Patients were categorized based on the percentage of cells harboring these deletions.

Main Results:

• A high burden of 17p del (>33%) was significantly associated with shorter lymphocyte doubling time (LDT), time to first treatment (TTFT), and progression-free survival (PFS).
• Conversely, an 11q del subclone burden (>30%) did not show a significant impact on LDT, TTFT, or PFS.
• These findings highlight the differential prognostic value of these two cytogenetic abnormalities.

Conclusions:

• Quantification of the 17p deletion subclone burden, specifically at a threshold of >33%, can enhance the risk stratification of CLL patients.
• This quantitative approach provides more refined prognostic information compared to a simple presence/absence assessment.
• Further investigation into the clinical utility of precise subclone burden quantification is warranted for personalized CLL management.